Biological mechanisms of atropine in myopia control (Review).

Mol Med RepAug 21, 2026 (epub)
Clinical ResearchOphthalmologyOpen access

Qin Zhu, Guanglong Zhou, Lingguo Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examines the biological mechanisms of atropine in controlling myopia, a progressive disease affecting billions globally. The review highlights atropine's effectiveness in slowing myopia progression in children, while emphasizing the need for further research to fully understand its mechanisms of action.

Key findings

  • The World Health Organization estimated 2.6 billion individuals were myopic in 2020, projected to rise to 3.364 billion by 2030.
  • Atropine is recognized as an effective pharmacological option for slowing myopia progression in children.
  • The review discusses the epidemiology, pathogenesis, effects, and side effects of myopia and atropine.

Why it matters

Understanding the mechanisms of atropine in myopia control is crucial for clinicians to optimize treatment strategies and improve patient outcomes in a condition that poses significant public health challenges.

Source

PubMed · PMID 42627050Free full text on PubMed Central

Published in Mol Med Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.